February 2017, Volume 3, Issue 3

February 2017

Volume 3, Issue 3

This issue features highlights from the 2016 ASH Annual Meeting, a look at the dangers of predatory publishing, and more.

Table of Contents

February 2017 Issue

Another Clinical Research Secret

Wednesday, February 1st, 2017
In the December 2016 Editor’s Corner (“So You Say You Want to Be a Clinical Researcher?”), Mikkael A. Sekeres, MD, MS, offered advice for...

Microphone Moment

Wednesday, February 1st, 2017
Entering Monday’s oral abstract session at the 2016 ASH Annual Meeting, my goals were twofold: to see some great science that may influence how...

February 2017 Issue

ASH Program for Future Clinical Researchers, Highlights of ASH, and more

Wednesday, February 1st, 2017
ASH Offers Program for Future Clinical Researchers Deadline for Application Fast Approaching  Hematology fellows and junior faculty interested in a career in clinical research are...

Remembering Peter C. Nowell, MD, Niels Borregaard, MD, PhD, Laurence Boxer, MD, and more

Wednesday, February 1st, 2017
Peter C. Nowell, MD (1928-2016) Peter C. Nowell, MD, an acclaimed researcher and co-discoverer of the Philadelphia chromosome, which pointed for the first time to...

February 2017 Issue

Affordable Care Act: Exit, Stage Right

Wednesday, February 1st, 2017
The rollback of the Affordable Care Act (ACA) is underway. Within hours of taking the oath of office on January 20, President Donald Trump...

February 2017 Issue

February 2017: Navigating Clinical Trials

Wednesday, February 1st, 2017
A clinical trial is a controlled research study conducted by doctors and medical researchers to improve the care and treatment of people who have...

Should I give CHOP-based therapy to a patient with peripheral T-cell lymphoma NOS?

Wednesday, February 1st, 2017
This month, Eric D. Jacobsen, MD, weighs in on administering CHOP-based therapy to a patient diagnosed with peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). You...

February 2017 Issue

FDA Places Hold on Investigational Anemia Treatment

Wednesday, February 1st, 2017
The FDA has placed a clinical hold on further investigation of AG-519 – an oral pyruvate kinase-R activator for the treatment of anemia –...

FDA Grants Breakthrough Designation for JCAR017 for the Treatment of Non-Hodgkin Lymphoma

Wednesday, February 1st, 2017
The FDA granted breakthrough therapy designation for JCAR017 – a CD19-targeted chimeric antigen receptor (CAR) T-cell therapy – for patients with relapsed/refractory, aggressive large...

FDA Lifts Clinical Hold on Pacritinib for the Treatment of Myelofibrosis

Wednesday, February 1st, 2017
The U.S. Food and Drug Administration (FDA) has lifted the full clinical hold placed on all clinical trials of pacritinib – an oral kinase JAK2/FLT3 inhibitor...

DEA Revises Registration Renewal Process … Twice

Wednesday, February 1st, 2017
In November 2016, the U.S. Department of Justice’s Drug Enforcement Administration (DEA) announced significant changes to its registration renewal process effective January 1, 2017....

Is It Safe to Eliminate CHOP Consolidation Therapy for Patients With CD20+ Post-Transplant Lymphoproliferative...

Wednesday, February 1st, 2017
Results from the phase II PTLD-1 (Sequential Treatment of CD20-Positive Post-Transplant Lymphoproliferative Disorder) trial established sequential treatment with four cycles of weekly rituximab followed...

Severe Fatigue Affects Survival and Social Reintegration for Hodgkin Lymphoma Survivors

Wednesday, February 1st, 2017
Approximately 40 percent of patients with Hodgkin lymphoma (HL) experience persistent fatigue, a chronic symptom that can affect patients years after successful treatment. In...

Assessing Lenalidomide Plus Rituximab for Patients With MALT Lymphoma

Wednesday, February 1st, 2017
Patients with advanced mucosa-associated lymphoid tissue (MALT) lymphoma are often treated with chemotherapy-based regimens; however, because of the indolent course of the disease, researchers...

Where Does Clofarabine Fit in the Treatment of Patients With Acute Myeloid Leukemia?

Wednesday, February 1st, 2017
Adding clofarabine – a second-generation nucleoside analogue – to a standard induction regimen reduced the risk of relapse for patients with newly diagnosed acute...

Long-Term Analysis Identifies Encouraging Trends in Hemophilia A Care

Wednesday, February 1st, 2017
From 1999 to 2010, bleeding events among U.S. patients with hemophilia A have dropped dramatically, coinciding with a marked increase in the use of...

Combining ATRA With ATO With or Without Gemtuzumab Ozogamicin Produces Durable Responses in Patients...

Wednesday, February 1st, 2017
The combination of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO), with or without the addition of gemtuzumab ozogamicin (GO), is a safe and effective...

February 2017 Issue

Double Hematopoietic Cell Transplantation Extends Progression-Free Survival Over Single Transplant in Myeloma Patients

Wednesday, February 1st, 2017
Following bortezomib-based induction therapy, patients with newly diagnosed multiple myeloma (MM) who received double autologous hematopoietic cell transplantation (AHCT) had longer progression-free survival (PFS)...

Does the Addition of ATLG Improve Outcomes After Allogeneic Transplantation?

Wednesday, February 1st, 2017
Previous studies have suggested that adding anti-T lymphocyte globulin (ATLG) to the treatment regimen for patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) could reduce...

For Patients on Dialysis With Venous Thromboembolism, Low-Molecular-Weight Heparin May Be a Better Option...

Wednesday, February 1st, 2017
Low-molecular-weight heparins (LMWHs) are not traditionally used to treat venous thromboembolism (VTE) in patients on dialysis, but results from a study presented at the...
SHARE